naringenin has been researched along with donepezil in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, X; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Aswar, M; Bhutada, P; Kaulaskar, S; Otari, K; Rahigude, A | 1 |
| He, Y; Liu, W; Mi, J; Sang, Z; Wu, A; Yang, J; Zhou, Y; Zhu, G | 1 |
3 other study(ies) available for naringenin and donepezil
| Article | Year |
|---|---|
The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Development; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Structure-Activity Relationship; Zebrafish | 2020 |
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Donepezil; Estrogen Antagonists; Fat Emulsions, Intravenous; Flavanones; Glutathione; Hypoglycemic Agents; Indans; Lipid Peroxidation; Male; Memory Disorders; Nitric Oxide; Parasympathetic Nervous System; Pioglitazone; Piperidines; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Thiazolidinediones | 2012 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Drug Development; Flavanones; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2022 |